Business
Notice of AGM
Notice of AGM.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 5306A Futura Medical PLC 30 May 2019 \n\n \nNotice of AGM and Annual Report\n30 May 2019\nFutura Medical plc (AIM: FUM) (\"Futura\" or the \"Company\"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, announces that its Annual General Meeting (\"AGM\") will be held at 10am on 24 June 2019 at the offices of Liberum at Ropemaker Place, 25 Ropemaker Street, London EC2Y 9LY.\nFutura's annual report and accounts for the year ended 31 December 2018 (the \"Annual Report\") is available to shareholders as an electronic communication pursuant to the Companies Act 2006 and is now available at the Company's website www.futuramedical.com, along with the notice of AGM.\nShareholders who would like to attend the AGM are invited to contact Optimum on +44 (0)203 950 9144 or email [email protected]\nFor further information please contact:\nFutura Medical plc \nJames Barder, Chief Executive\nAngela Hildreth, Finance Director and COO\nEmail: [email protected]\nTel: +44 (0) 1483 685 670\n\nLiberum (Nominated Adviser and Broker)\nBidhi Bhoma\nEuan Brown\nKane Collings\nTel: +44 (0) 20 3100 2000\n \nFor media enquiries please contact:\nOptimum Strategic Communications\nMary Clark/ Hollie Vile/ Ellie Blackwell\nEmail: [email protected]\nTel: +44 (0) 203 950 9144\n \nNotes to editors:\nAbout Futura Medical plc\nFutura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.\n \nFutura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com\n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Informati...